http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9605852-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ea200c15bbfe5bbb2493b6419fa853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b157f22b1908d6919bd5e64bb04b7703 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 |
| filingDate | 1995-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d9987209688c7cf984c553769b070c2 |
| publicationDate | 1996-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9605852-A1 |
| titleOfInvention | Treatment of inflammatory diseases of the gastro-intestinal tract |
| abstract | The present invention provides use of a peptide or ligand in the manufacture of a medicament for the treatment of certain inflammatory diseases of the gastro-intestinal tract, such as coeliac disease, Crohn's disease, ulcerative colitis etc., and a method of treatment of the diseases comprising administering an effective dose of a medicament comprising the peptide or ligand. The peptide has not more than 20 amino acid residues, and comprises a thiol-active cysteine residue and at least two positively charged amino acid residues situated at, adjacent or near to the N terminus or at, adjacent or near to the C terminus or at, adjacent or near to both termini; or this peptide and a pharmaceutically acceptable diluent or carrier. Preferably the peptide or analog comprises amino acid residues having a sequence selected from the group which comprises: Cys-Lys-Lys, His-Cys-Lys-Lys (SEQ ID NO:1). Also, the invention can provide a method of treatment of IDGIT comprising administering an effective dose of a peptide or analogue thereof having general formula (I) wherein m is 0 or 1, n is 0 or 1 and m + n is 1 or 2; J?1 and J2¿ represent sequences of positively charged amino acid residues; Z?1, Z2, B1 and B2¿ represent sequences of residues of positively charged, negatively charged or neutral amino acid residues or sequences of any mixture of positively charged, negatively charged or neutral amino acid residues; x = 0 or 1, y = 0 or 1, and x + y = 1 or 2; c = 0 to 4, d = 0 to 4; and a = 0 to 18 and b = 0 to 18 with the proviso that when m = 0 at least one of B?2 and Z2¿ is a positively charged amino acid residue and when n is 0 at least one of B?1 and Z1¿ is a positively charged amino acid residue, and when m = n = 1 and y is 0 at least one of Z?1, B1, B2 and Z2¿ is a positively charged amino acid residue and when m = n = 1 and x = 0 at least one of Z?1, B1, B2 and Z2¿ is a positively charged amino acid residue: B?1 and B2¿ may also represent a non-peptide spacer arm of a length equivalent to that determined by the length of b and c residues of amino acids. |
| priorityDate | 1994-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.